Ray Dalio's BIO Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 1,684 shares of Bio-Rad Laboratories, Inc. (BIO) worth $469,415, representing 0.00% of the portfolio. First purchased in 2015-Q3, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in BIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2017, adding 19,255 shares. Largest reduction occurred in Q4 2023, reducing 15,988 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1,684 | New Buy | 1,684 | $278.75 |
| Q4 2025 | -10,632 | Sold Out | 0 | $0.00 |
| Q3 2025 | +10,632 | New Buy | 10,632 | $280.39 |
| Q1 2024 | -771 | Sold Out | 0 | $0.00 |
| Q4 2023 | -15,988 | Reduce 95.40% | 771 | $322.89 |
| Q3 2023 | +290 | Add 1.76% | 16,759 | $358.45 |
| Q2 2023 | +15,666 | Add 1950.93% | 16,469 | $379.12 |
| Q1 2023 | -11,171 | Reduce 93.29% | 803 | $479.02 |
| Q4 2022 | +3,563 | Add 42.36% | 11,974 | $420.49 |
| Q3 2022 | +5,178 | Add 160.16% | 8,411 | $417.19 |
| Q2 2022 | +2,848 | Add 739.74% | 3,233 | $494.90 |
| Q1 2022 | +385 | New Buy | 385 | $563.64 |
| Q1 2019 | -6,590 | Sold Out | 0 | $0.00 |
| Q4 2018 | +4,574 | Add 226.88% | 6,590 | $232.17 |
| Q3 2018 | +184 | Add 10.04% | 2,016 | $313.00 |
| Q2 2018 | -1,777 | Reduce 49.24% | 1,832 | $288.76 |
| Q1 2018 | -15,646 | Reduce 81.26% | 3,609 | $250.21 |
| Q4 2017 | +19,255 | New Buy | 19,255 | $238.69 |
| Q4 2015 | -2,978 | Sold Out | 0 | $0.00 |
| Q3 2015 | +2,978 | New Buy | 2,978 | $134.32 |
Ray Dalio's Bio-Rad Laboratories Investment FAQs
Ray Dalio first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2015, acquiring 2,978 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Bio-Rad Laboratories, Inc. (BIO) for 20 quarters since Q3 2015.
Ray Dalio's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2017, adding 19,255 shares worth $4.6 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 1,684 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $469,415.
As of the Q1 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 19,255 shares, as reported at the end of Q4 2017.